Multicenter clinical trials are needed for further validation of our initial results.
Further well designed, larger controlled trials are needed for specific psychiatric and neurological disorders where the evidence is favorable.
In conclusion, more comparative effectiveness trials are needed for CLEWs, for which head-to-head comparisons are fewer than those for psoriasis and AV.
Larger, prospective trials are needed for further clarification of these results.
However, more safety trials are needed for agents like nicotine replacement therapy and bupropion.
Trials are needed for investigating the use, the drug choice and the timing of antifungal prophylaxis for such high-risk patients.
Considering that RTR are a high-risk group for hypovitaminosis D, well-designed interventional trials are needed for the development of effective strategies aimed at the prevention and treatment of hypovitaminosis D in such patients.
In addition, other biofluids such as saliva and urine also have the potential for detecting EGFR mutations but large prospective clinical trials are needed for establishing the clinical utility.
As clinical response sometimes occurs even when susceptibility testing in vitro suggests that the antimicrobial agent used is ineffective, controlled clinical trials are needed for these infections in different geographic regions of Africa.
There are almost no data regarding the treatment of patients with HER-2-positive ABC who relapse on or shortly after adjuvant trastuzumab and urgent trials are needed for this poor prognosis population.
